摘要
尼达尼布是一种三重血管激酶抑制剂,可靶向抑制血管内皮生长因子受体、血小板衍生生长因子受体和成纤维细胞生长因子受体通路,避免肿瘤转向正常逃逸机制,已被欧洲药品管理局批准联合多西他赛用于治疗一线化疗后局部转移或局部复发的晚期腺癌类型非小细胞肺癌(NSCLC)。至今为止,尼达尼布治疗NSCLC的研究已取得了一系列新进展,大量研究证实尼达尼布单药或联合治疗NSCLC均具有较好疗效,且不良反应轻微可耐受,其常见不良反应为肝功能受损、恶心、呕吐和腹泻等。
Nintedanib is a triple vascular kinase inhibitor that blocks vascular endothelial growth factor receptor, platelet-derived growth factor receptor and fibroblast growth factor receptor pathway, prevents the tumor from turning to normal escape mechanism. It has been approved for the combination of docetaxel in the treatment of locally metastatic or locally recurrent advanced non-small cell lung cancer(NSCLC) of adenocarcinoma tumor histology by European Medicines Agency. Up to now, the researches about nintedanib in the treatment of NSCLC has made a series of new progress, a large number of studies have confirmed that nintedanib alone or combined treatment of NSCLC has a good effect, and the adverse reactions are slightly and tolerated.The common adverse reactions were liver function damage, nausea, vomiting, diarrhea and so on.
作者
苏建
曾林祥
SU Jian;ZENG Lin-xiang(Department of Respiratory and Critical Care Medicine,the Second Affiliated Hospital of None hang University,None hang JIANGXI 330006,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2019年第11期653-657,共5页
Chinese Journal of New Drugs and Clinical Remedies
关键词
尼达尼布
癌
非小细胞肺
血管生成抑制剂
nintedanib
carcinoma,non-small-cell lung
angiogenesis inhibitors
